Baker Bros. Advisors (GP) LLC executed the largest insider purchase in KOD history, acquiring nearly 197,000 shares at $89.86 just days after the stock surged nearly 180% on positive wet AMD trial data. This high-profile bet by a major biotech investor suggests conviction in the company's competitive positioning against Eylea following the DAYBREAK trial readout.
Price context
The stock has experienced explosive momentum, rallying 189.26% over the last 5 days and 143.87% over the last 30 days to reach a current price of $91.16, which is only 4.81% below its 52-week high of $95.77.
Catalysts to watch
1) Upcoming BLA filing for Zenkuda and tabirafusp-tedromer (cited in 'KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears' dated 2026-09-29). 2) The 'largest insider purchase ever' cluster itself, as Baker Bros. Advisors executed this massive buy on 2026-09-28.
Risks
The stock faces significant dilution risk, as recent analysis notes the company is a 'cash-burning biotech with no revenue and a likely share offering' (cited in 'A $32 Biotech Became a $90 Biotech Overnight' dated 2026-09-30).
AI-generated context from public data. Not investment advice. Verify before trading.